Advisors Asset Management Inc. Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

Advisors Asset Management Inc. boosted its stake in Pfizer Inc. (NYSE:PFE) by 8.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 748,468 shares of the biopharmaceutical company’s stock after buying an additional 59,283 shares during the period. Advisors Asset Management Inc.’s holdings in Pfizer were worth $19,857,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brooktree Capital Management increased its stake in Pfizer by 1.2% during the fourth quarter. Brooktree Capital Management now owns 115,383 shares of the biopharmaceutical company’s stock worth $3,061,000 after purchasing an additional 1,389 shares during the period. PDS Planning Inc increased its stake in Pfizer by 4.0% during the fourth quarter. PDS Planning Inc now owns 32,708 shares of the biopharmaceutical company’s stock worth $868,000 after purchasing an additional 1,262 shares during the period. Retirement Planning Co of New England Inc. increased its stake in Pfizer by 3.3% during the fourth quarter. Retirement Planning Co of New England Inc. now owns 24,695 shares of the biopharmaceutical company’s stock worth $655,000 after purchasing an additional 779 shares during the period. Mystic Asset Management Inc. increased its stake in Pfizer by 126.6% during the fourth quarter. Mystic Asset Management Inc. now owns 174,006 shares of the biopharmaceutical company’s stock worth $4,616,000 after purchasing an additional 97,231 shares during the period. Finally, Leelyn Smith LLC increased its stake in Pfizer by 6.4% during the fourth quarter. Leelyn Smith LLC now owns 87,767 shares of the biopharmaceutical company’s stock worth $2,328,000 after purchasing an additional 5,311 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 1.3 %

Shares of NYSE:PFE opened at $26.07 on Tuesday. The stock’s 50-day moving average price is $26.22 and its two-hundred day moving average price is $27.10. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm has a market cap of $147.72 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business posted $0.10 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, March 12th. Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.